Nexalin Advances HALO Clarity Clinical Trial for Insomnia Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Launch: Nexalin Technology is advancing its HALO Clarity program by initiating a pivotal clinical trial aimed at supporting a de novo submission to the U.S. FDA for moderate to severe insomnia treatment, which is expected to provide a competitive edge in the multi-billion-dollar insomnia market.
- Technological Innovation: The company positions its non-drug Deep Intracranial Frequency Stimulation (DIFS) technology as a potential alternative to address insomnia affecting approximately 30 million adults in the U.S., particularly as many patients express dissatisfaction with current treatment options due to concerns about dependency and tolerability.
- Trial Design: The HALO Clarity study is a randomized, triple-blinded, sham-controlled trial designed to enroll at least 150 adults, utilizing a fully decentralized model that allows participants to complete treatments and assessments remotely through Nexalin's NeuroCare virtual clinic, thereby broadening patient access.
- Strategic Implications: This trial builds on previously published clinical data demonstrating significant improvements in sleep parameters, marking a major milestone in Nexalin's strategy to expand its DIFS platform into high-prevalence neuropsychiatric conditions, with results expected to form the foundation for the company's planned FDA submission.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXL
About NXL
Nexalin Technology, Inc. is a medical device company. It engaged in design and development of neurostimulation products for mental health epidemics. It has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. It also operates PONM, which is a digital health platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nexalin Showcases Clinical Results at Neuromodulation Conference
- Significant Anxiety Improvement: Nexalin's DIFS™ treatment platform achieved a 77.8% anxiety response rate at the end of treatment, with durable effects observed at the 8-week follow-up, indicating the technology's potential for long-term market viability and commercial success.
- Depressive Symptoms Alleviated: The Hamilton Depression Rating Scale (HAMD) scores decreased by 9.90 points by the end of treatment, with 66.7% of patients meeting remission criteria, enhancing Nexalin's clinical reputation and potentially attracting further investment.
- Sustained Insomnia Improvement: Pittsburgh Sleep Quality Index (PSQI) scores significantly improved at the end of treatment and remained favorable at the 8-week follow-up, demonstrating the efficacy of Nexalin's approach across multiple neuropsychiatric domains, which may support its global expansion efforts.
- Favorable Tolerability Profile: No serious adverse events or seizures were reported during the clinical trial, showcasing the good tolerability of Nexalin's technology, which could enhance patient trust and facilitate market acceptance of its products.
See More
Nexalin's Clinical Trial Shows Significant Improvements in Anxiety and Depression
- Clinical Trial Results: Nexalin's 8-week clinical trial in Brazil demonstrated a 77.8% anxiety response rate at the end of treatment, indicating the effectiveness of its non-invasive deep frequency stimulation technology for generalized anxiety disorder.
- Rapid Improvement: By Session 5, Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 14.73 points, showcasing the technology's quick impact on anxiety symptoms, with significant improvements maintained at the 8-week follow-up.
- Favorable Tolerability: No serious adverse events, seizures, or manic/hypomanic switches were reported during the trial, reinforcing the favorable tolerability profile of Nexalin's technology and enhancing its potential applications in mental health.
- Market Strategy Support: The trial results provide crucial support for Nexalin's product launch and sales strategy in Brazil, highlighting the technology's potential to meet urgent patient needs for new treatment options.
See More
Nexalin Secures U.S. Patent to Strengthen Market Position
- Extended Patent Protection: Nexalin's newly issued U.S. patent extends intellectual property protection for its dynamic frequency stimulation method through 2042, further solidifying the company's competitive edge in non-invasive deep-brain neurostimulation, particularly in addressing significant unmet needs in anxiety, depression, and insomnia markets.
- Market Demand Alignment: The patent covers stimulation methods targeting anxiety, depression, and insomnia, which represent substantial global medical needs; Nexalin's HALO™ Clarity and NeuroCare™ strategies are centered around these markets, expected to drive future clinical and commercial success for the company.
- Technological Innovation and Application: Nexalin's DIFS™ platform is designed to penetrate deeper brain structures for non-invasive treatment, and the patent's issuance will help protect its unique therapeutic approach, supporting long-term development in drug-free treatment alternatives, especially within the virtual clinic model for home use.
- Strengthened Intellectual Property Strategy: The acquisition of this patent not only enhances Nexalin's intellectual property portfolio but also lays the groundwork for applications in other neurological conditions such as Alzheimer's disease, traumatic brain injury, and PTSD, which is anticipated to create long-term shareholder value and enhance market competitiveness.
See More
Australian Stock Market Shows Signs of Recovery
- Market Recovery Signs: The Australian stock market is showing signs of recovery after a significant A$45 billion downturn, with a modest 0.7% rise anticipated, indicating improved market sentiment driven by potential geopolitical resolutions and Wall Street's record highs.
- Undervalued Stock Opportunities: In the current volatile market, identifying undervalued stocks is crucial; the article explores three such opportunities on the ASX, including Navigator Global Investments, which has a market cap of approximately A$1.28 billion and is trading at A$2.6, significantly below its estimated future cash flow value of A$3.96, reflecting a 34.3% discount.
- Growth Potential of PolyNovo: PolyNovo Limited, with a market cap of A$842.83 million, is trading at A$1.22, below its estimated cash flow value of A$1.56, and is expected to see earnings grow by 37% annually, significantly outpacing the Australian market's 12% growth rate, indicating strong financial growth potential.
- Smart Parking's Financial Outlook: Smart Parking Limited, valued at A$355.10 million, is trading at A$0.86, below its estimated cash flow value of A$1.34; despite a decline in profit margins, earnings are forecasted to grow by 39.6% annually, suggesting an optimistic financial performance ahead.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
U.S. Congress Supports Nexalin's Neurostimulation Research for Veterans
- Congressional Support: The U.S. House Appropriations Committee's report language directs the VA to support research on non-invasive deep brain neurostimulation technologies, highlighting recognition of Nexalin's technology and potentially opening up more funding and market opportunities for the company.
- Funding Details: The bill allocates $945 million for VA Medical Research, emphasizing the importance of addressing traumatic brain injury (TBI) and mental health, with Nexalin's DIFS™ technology likely to benefit from this funding.
- Technology Distinction: The new report language clearly differentiates traditional stimulation devices from Nexalin's DIFS™ waveform, indicating Nexalin's unique position in the non-invasive neurostimulation field, which may facilitate its adoption in veteran healthcare.
- Clinical Research Advancement: Nexalin is accelerating its clinical research on DIFS™ technology at UC San Diego, aimed at gathering data to support its efficacy in treating TBI and PTSD, further solidifying its leadership position in the market.
See More
Nexalin Showcases Clinical Results at Neuromodulation Conference
- Significant Anxiety Improvement: Nexalin's DIFS™ treatment platform achieved a 77.8% anxiety response rate at the end of treatment, with durable effects observed at the 8-week follow-up, indicating the technology's potential for long-term market viability and commercial success.
- Depressive Symptoms Alleviated: The Hamilton Depression Rating Scale (HAMD) scores decreased by 9.90 points by the end of treatment, with 66.7% of patients meeting remission criteria, enhancing Nexalin's clinical reputation and potentially attracting further investment.
- Sustained Insomnia Improvement: Pittsburgh Sleep Quality Index (PSQI) scores significantly improved at the end of treatment and remained favorable at the 8-week follow-up, demonstrating the efficacy of Nexalin's approach across multiple neuropsychiatric domains, which may support its global expansion efforts.
- Favorable Tolerability Profile: No serious adverse events or seizures were reported during the clinical trial, showcasing the good tolerability of Nexalin's technology, which could enhance patient trust and facilitate market acceptance of its products.
See More
Nexalin's Clinical Trial Shows Significant Improvements in Anxiety and Depression
- Clinical Trial Results: Nexalin's 8-week clinical trial in Brazil demonstrated a 77.8% anxiety response rate at the end of treatment, indicating the effectiveness of its non-invasive deep frequency stimulation technology for generalized anxiety disorder.
- Rapid Improvement: By Session 5, Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 14.73 points, showcasing the technology's quick impact on anxiety symptoms, with significant improvements maintained at the 8-week follow-up.
- Favorable Tolerability: No serious adverse events, seizures, or manic/hypomanic switches were reported during the trial, reinforcing the favorable tolerability profile of Nexalin's technology and enhancing its potential applications in mental health.
- Market Strategy Support: The trial results provide crucial support for Nexalin's product launch and sales strategy in Brazil, highlighting the technology's potential to meet urgent patient needs for new treatment options.
See More
Nexalin Secures U.S. Patent to Strengthen Market Position
- Extended Patent Protection: Nexalin's newly issued U.S. patent extends intellectual property protection for its dynamic frequency stimulation method through 2042, further solidifying the company's competitive edge in non-invasive deep-brain neurostimulation, particularly in addressing significant unmet needs in anxiety, depression, and insomnia markets.
- Market Demand Alignment: The patent covers stimulation methods targeting anxiety, depression, and insomnia, which represent substantial global medical needs; Nexalin's HALO™ Clarity and NeuroCare™ strategies are centered around these markets, expected to drive future clinical and commercial success for the company.
- Technological Innovation and Application: Nexalin's DIFS™ platform is designed to penetrate deeper brain structures for non-invasive treatment, and the patent's issuance will help protect its unique therapeutic approach, supporting long-term development in drug-free treatment alternatives, especially within the virtual clinic model for home use.
- Strengthened Intellectual Property Strategy: The acquisition of this patent not only enhances Nexalin's intellectual property portfolio but also lays the groundwork for applications in other neurological conditions such as Alzheimer's disease, traumatic brain injury, and PTSD, which is anticipated to create long-term shareholder value and enhance market competitiveness.
See More
Australian Stock Market Shows Signs of Recovery
- Market Recovery Signs: The Australian stock market is showing signs of recovery after a significant A$45 billion downturn, with a modest 0.7% rise anticipated, indicating improved market sentiment driven by potential geopolitical resolutions and Wall Street's record highs.
- Undervalued Stock Opportunities: In the current volatile market, identifying undervalued stocks is crucial; the article explores three such opportunities on the ASX, including Navigator Global Investments, which has a market cap of approximately A$1.28 billion and is trading at A$2.6, significantly below its estimated future cash flow value of A$3.96, reflecting a 34.3% discount.
- Growth Potential of PolyNovo: PolyNovo Limited, with a market cap of A$842.83 million, is trading at A$1.22, below its estimated cash flow value of A$1.56, and is expected to see earnings grow by 37% annually, significantly outpacing the Australian market's 12% growth rate, indicating strong financial growth potential.
- Smart Parking's Financial Outlook: Smart Parking Limited, valued at A$355.10 million, is trading at A$0.86, below its estimated cash flow value of A$1.34; despite a decline in profit margins, earnings are forecasted to grow by 39.6% annually, suggesting an optimistic financial performance ahead.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
U.S. Congress Supports Nexalin's Neurostimulation Research for Veterans
- Congressional Support: The U.S. House Appropriations Committee's report language directs the VA to support research on non-invasive deep brain neurostimulation technologies, highlighting recognition of Nexalin's technology and potentially opening up more funding and market opportunities for the company.
- Funding Details: The bill allocates $945 million for VA Medical Research, emphasizing the importance of addressing traumatic brain injury (TBI) and mental health, with Nexalin's DIFS™ technology likely to benefit from this funding.
- Technology Distinction: The new report language clearly differentiates traditional stimulation devices from Nexalin's DIFS™ waveform, indicating Nexalin's unique position in the non-invasive neurostimulation field, which may facilitate its adoption in veteran healthcare.
- Clinical Research Advancement: Nexalin is accelerating its clinical research on DIFS™ technology at UC San Diego, aimed at gathering data to support its efficacy in treating TBI and PTSD, further solidifying its leadership position in the market.
See More
